menu
    • menu
    [{"orgOrder":0,"company":"Latigo Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"LTG-001","moa":"NaV1.8 Channel","graph1":"Neurology","graph2":"Phase II","graph3":"Latigo Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Latigo Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Latigo Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Latigo Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"LTG-001","moa":"NaV1.8 Channel","graph1":"Undisclosed","graph2":"Phase I","graph3":"Latigo Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Latigo Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Latigo Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Latigo Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"LTG-001","moa":"NaV1.8 Channel","graph1":"Neurology","graph2":"Phase II","graph3":"Latigo Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Latigo Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Latigo Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Latigo Biotherapeutics","sponsor":"Blue Owl Capital","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Series B Financing","leadProduct":"LTG-001","moa":"NaV1.8 Channel","graph1":"Neurology","graph2":"Phase II","graph3":"Latigo Biotherapeutics","amount2":0.14999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0.14999999999999999,"dosageForm":"Undisclosed","sponsorNew":"Latigo Biotherapeutics \/ Blue Owl Capital","highestDevelopmentStatusID":"8","companyTruncated":"Latigo Biotherapeutics \/ Blue Owl Capital"},{"orgOrder":0,"company":"Latigo Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"LTG-001","moa":"NaV1.8 Channel","graph1":"Neurology","graph2":"Phase II","graph3":"Latigo Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Latigo Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Latigo Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Latigo Biotherapeutics","sponsor":"Westlake Village BioPartners","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Series A Financing","leadProduct":"LTG-001","moa":"NaV1.8 Channel","graph1":"Neurology","graph2":"Phase II","graph3":"Latigo Biotherapeutics","amount2":0.14000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0.14000000000000001,"dosageForm":"Undisclosed","sponsorNew":"Latigo Biotherapeutics \/ Westlake Village BioPartners","highestDevelopmentStatusID":"8","companyTruncated":"Latigo Biotherapeutics \/ Westlake Village BioPartners"},{"orgOrder":0,"company":"Latigo Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"LTG-001","moa":"Nav1.8","graph1":"Neurology","graph2":"Phase II","graph3":"Latigo Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Latigo Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Latigo Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Latigo Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"LTG-321","moa":"Nav1.8","graph1":"Undisclosed","graph2":"Phase I","graph3":"Latigo Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Latigo Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Latigo Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Latigo Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Suzetrigine","moa":"SCN10A","graph1":"Undisclosed","graph2":"Phase I","graph3":"Latigo Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Latigo Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Latigo Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Latigo Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"LTG-305","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"Latigo Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Latigo Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Latigo Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Latigo Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Pregabalin","moa":"Voltage-gated calcium channel","graph1":"Undisclosed","graph2":"Phase I","graph3":"Latigo Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Latigo Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Latigo Biotherapeutics \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by Latigo Biotherapeutics

    Menu

    Latigo Biotherapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Latigo Biotherapeutics

                            U.S.A arrow
                            AAPS
                            Not Confirmed

                            Latigo Biotherapeutics

                            U.S.A arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : LTG-321

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Phase 1 Single and Multiple Ascending Dose of LTG-321 in Healthy Participants

                            Details : LTG-321 is a Other Small Molecule drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of unspecified medical condition.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            August 07, 2025

                            Lead Product(s) : LTG-321

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Latigo Biotherapeutics

                            U.S.A arrow
                            AAPS
                            Not Confirmed

                            Latigo Biotherapeutics

                            U.S.A arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : LTG-001

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            An Efficacy and Safety Study of LTG-001 Following Abdominoplasty

                            Details : LTG-001 is a Other Small Molecule drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Acute Pain.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            August 03, 2025

                            Lead Product(s) : LTG-001

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Latigo Biotherapeutics

                            U.S.A arrow
                            AAPS
                            Not Confirmed

                            Latigo Biotherapeutics

                            U.S.A arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Suzetrigine

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Pharmacodynamic Study of 100mg Suzegtrigine vs Placebo in Healthy Male Adults

                            Details : Suzetrigine is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            May 14, 2025

                            Lead Product(s) : Suzetrigine

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Latigo Biotherapeutics

                            U.S.A arrow
                            AAPS
                            Not Confirmed

                            Latigo Biotherapeutics

                            U.S.A arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : LTG-001

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : Blue Owl Capital

                            Deal Size : $150.0 million

                            Deal Type : Series B Financing

                            DEALS_DEV arrow-down

                            Latigo Secures $150M Series B for Non-Opioid Pain Treatment

                            Details : The financing aims to support the clinical development of LTG-001, a highly selective Nav1.8 inhibitors currently in clinical development for the non-opioid treatment of pain.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            March 17, 2025

                            Lead Product(s) : LTG-001

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : Blue Owl Capital

                            Deal Size : $150.0 million

                            Deal Type : Series B Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Latigo Biotherapeutics

                            U.S.A arrow
                            AAPS
                            Not Confirmed

                            Latigo Biotherapeutics

                            U.S.A arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : LTG-001

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Latigo gets FDA Fast Track for LTG-001, A Nav1.8 Inhibitor for Acute Pain Treatment

                            Details : LTG-001 is an oral, selective Nav1.8 inhibitor, currently being evaluated in healthy volunteers and intended to treat acute and chronic pain.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 03, 2025

                            Lead Product(s) : LTG-001

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Latigo Biotherapeutics

                            U.S.A arrow
                            AAPS
                            Not Confirmed

                            Latigo Biotherapeutics

                            U.S.A arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : LTG-001

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            This is a Study Evaluating the Efficacy and Safety of LTG-001 for Acute Pain After Surgical Removal of Impacte...

                            Details : LTG-001 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Pain, Postoperative.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            January 14, 2025

                            Lead Product(s) : LTG-001

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Latigo Biotherapeutics

                            U.S.A arrow
                            AAPS
                            Not Confirmed

                            Latigo Biotherapeutics

                            U.S.A arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pregabalin

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Pharmacodynamic Study of 300mg Pregabalin vs Placebo in Healthy Male Adults

                            Details : Pregabalin is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            September 19, 2024

                            Lead Product(s) : Pregabalin

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Latigo Biotherapeutics

                            U.S.A arrow
                            AAPS
                            Not Confirmed

                            Latigo Biotherapeutics

                            U.S.A arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : LTG-001

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Latigo Biotherapeutics Reports Positive Phase 1 Data for Non-Opioid Pain Drug

                            Details : LTG-001 is an oral, selective Nav1.8 inhibitor, currently in Phase 1 clinical trial in healthy volunteers and intended to treat acute and chronic pain.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            August 19, 2024

                            Lead Product(s) : LTG-001

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Latigo Biotherapeutics

                            U.S.A arrow
                            AAPS
                            Not Confirmed

                            Latigo Biotherapeutics

                            U.S.A arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : LTG-305

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Phase 1 Single and Multiple Ascending Dose Study of LTG-305 Administered Orally in Healthy Participants

                            Details : LTG-305 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            August 15, 2024

                            Lead Product(s) : LTG-305

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Latigo Biotherapeutics

                            U.S.A arrow
                            AAPS
                            Not Confirmed

                            Latigo Biotherapeutics

                            U.S.A arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : LTG-001

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : Westlake Village BioPartners

                            Deal Size : $135.0 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            Latigo Debuts with Series A Financing for Non-Opioid Pain Medicines Development

                            Details : The funding aims to support the development of LTG-001, which is an oral, selective Nav1.8 inhibitor currently in Phase 1 trial in healthy volunteers and intended to treat acute and chronic pain.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            February 14, 2024

                            Lead Product(s) : LTG-001

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : Westlake Village BioPartners

                            Deal Size : $135.0 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth